CMS Open Payments · Program Year 2024
Mobius Therapeutics, LLC
Mobius Therapeutics, LLC reported $5,309.00 across General Payments, Research, and Ownership to 2 physicians and teaching hospitals across 4 transactions.
- $5.3K
- All-tracks total
- 4
- Transactions
- 2
- Recipients
- #1707
- of 1,925 companies
Mobius Therapeutics, LLC reported $5,309.00 across all CMS Open Payments tracks (General + Research + Ownership) to 2 physicians and teaching hospitals in Program Year 2024 - ranking #1707 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,000.00, averaging $2.7K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer mobius-therapeutics-llc Mobius Therapeutics, LLC
$5.3K · #1707/1,925 · 0.0% industry · PY2024
- TOT $5.3K
- RANK #1707
- SHARE 0.0%
- TXN 4
- RCP 2
- CAT 1
- GEN $1.0K
- TOP1 50.0%
- PY 2024
Volume peers
Nearest volume peer: Canon Healthcare USA, Inc. ($5.3K)
Mobius Therapeutics, LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Mobius Therapeutics, LLC
Rank #1707 of 1,925 companies in CMS Open Payments for 2024 belongs to Mobius Therapeutics, LLC, which reported $5,309.00 across 4 transactions to 2 recipients - a comparatively small 0.0% slice of all industry payments reported nationwide for the year. Averages work out to $1.3K per transaction and $2.7K per recipient.
2 transactions worth $1.0K make "Compensation for Services Other Than Consulting" the top general-payment category in the 1-category breakdown below, 100.0% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Mobius Therapeutics, LLC made 1 types of general payments. "Compensation for Services Other Than Consulting" is the largest category at $1.0K, 100.0% of General Payments.
How Mobius Therapeutics, LLC divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $1.0K | 2 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $1,000.00 (100.0%) of $1,000.00 in this company's General Payments records across 2 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Mobius Therapeutics, LLC
The five named recipients with the highest reported General Payments from this company
- 1
Arsham Sheybani
$500.00 across 1 reported transactions
- 2
Marlene Moster
$500.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Mobius Therapeutics, LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Mobius Therapeutics, LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Mobius Therapeutics, LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
ASD Specialty Healthcare, LLC
Summit Surgical Corp.
Aquestive Therapeutics, Inc.
Granata Bio Corporation
Karl Storz Endovision, Inc.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.